U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07047703) titled 'EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)' on June 24.
Brief Summary: GRWD0715 is an orally administered, selective inhibitor of the Endoplasmic Reticulum Aminopeptidase 1 [ERAP1] enzyme being explored as a potential new treatment for axial spondyloarthritis (axSpA), a long term condition caused by inflammation predominantly affecting the sacroiliac joints (SIJs) and spine.
Study Start Date: Aug. 31
Study Type: INTERVENTIONAL
Condition:
Axial Spondyloarthritis (AxSpA)
Intervention:
DRUG: Part A - Single Ascending Dose (SAD) in Healthy Human Volunteers
Participants in Part A will receive a single dose of GRW...